文献速递免疫规划

11价和12价肺炎球菌不可分型流感嗜血杆菌蛋白D结合疫苗(11vPHiD-CV、12vPHiD-CV)在婴儿中的免疫原性和安全性:II期随机多中心研究结果

Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
PubMed 文献 · Vaccine · 2018-07-24

这项II期部分盲法多中心研究将健康婴儿按1:1:1:1随机分配接种11vPHiD-CV、12vPHiD-CV、PHiD-CV或PCV13,在2、3、4月龄基础免疫和12-15月龄加强免疫,并与DTPa-HBV-IPV/Hib联合接种。结果显示11vPHiD-CV对9/11个血清型、12vPHiD-CV对10/12个血清型同时达到预设免疫非劣效标准,安全性特征与对照疫苗相当。

要点

  • 11vPHiD-CV对9/11血清型(除23F和19A外)达到免疫非劣效标准。
  • 12vPHiD-CV对10/12血清型(除19A和6A外)达到免疫非劣效标准。
  • 研究疫苗安全性特征与PHiD-CV和PCV13相当,未记录死亡事件。

核心结论

  • 添加19A和6A CRM197结合物未改变PHiD-CV结合物的免疫原性。
  • 两种研究疫苗加强免疫后对10种共同血清型的免疫应答与PHiD-CV相似。
  • 研究疫苗的安全性和反应原性特征与PHiD-CV相当。

研究设计与样本

  • II期、部分盲法、多中心研究(NCT01204658)。
  • 健康婴儿按1:1:1:1随机分配接种11vPHiD-CV、12vPHiD-CV、PHiD-CV或PCV13。
  • 在2、3、4月龄基础免疫,12-15月龄加强免疫,与DTPa-HBV-IPV/Hib联合接种。
  • 951名儿童接受至少1剂基础免疫,919名接受加强免疫。

主要发现

  • 11vPHiD-CV对9/11血清型(除23F和19A外)同时达到预设免疫非劣效标准。
  • 12vPHiD-CV对10/12血清型(除19A和6A外)同时达到预设免疫非劣效标准。
  • 基础免疫后PHiD-CV各血清型抗体浓度≥0.2 μg/mL的儿童百分比≥96.7%(6B除外[≥75.2%],23F除外[≥81.1%])。
  • 加强免疫后PHiD-CV各血清型抗体浓度≥0.2 μg/mL的儿童百分比≥98.1%。
  • 除血清型1外,基础免疫和加强免疫后PHiD-CV各血清型调理吞噬活性滴度≥8的儿童百分比分别≥81.0%和≥93.9%。

关键数值与推荐

  • 免疫非劣效性判定依据:基础免疫后肺炎球菌抗体浓度≥0.2 μg/mL的婴儿百分比和抗体几何平均浓度。
  • 共同血清型与PHiD-CV比较,血清型19A和6A与PCV13比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We assessed 2 investigational 11- and 12-valent vaccines, containing capsular polysaccharides of 10 serotypes as in the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) and CRM197-conjugated capsular polysaccharides of serotypes 19A (11-valent) or 19A and 6A (12-valent). METHODS: In this phase II, partially-blind, multicentre study (NCT01204658), healthy infants were randomised (1:1:1:1) to receive 11vPHiD-CV, 12vPHiD-CV, PHiD-CV, or 13-valent CRM197-conjugate pneumococcal vaccine (PCV13), at 2, 3, and 4 (primary series), and 12-15 months of age (booster dose), co-administered with DTPa-HBV-IPV/Hib. Confirmatory objectives assessed non-inferiority of investigational vaccines to comparators (PHiD-CV for common serotypes; PCV13 for 19A and 6A), in terms of percentage of infants with pneumococcal antibody concentrations ≥0.2 μg/mL and antibody geometric mean concentrations, post-primary vaccination. Reactogenicity and safety were assessed. RESULTS: 951 children received ≥1 primary dose, 919 a booster dose. Pre-defined immunological non-inferiority criteria were met simultaneously for 9/11 11vPHiD-CV serotypes (all except 23F and 19A) and 10/12 12vPHiD-CV serotypes (all except 19A and 6A); thus, non-inferiority objectives were reached. For each PHiD-CV serotype, percentages of children with antibody concentrations ≥0.2 µg/mL were ≥96.7% post-primary (except 6B [≥75.2%] and 23F [≥81.1%]), and ≥98.1% post-booster vaccination. For each PHiD-CV serotype except serotype 1, ≥81.0% and ≥93.9% of children had opsonophagocytic activity titres ≥8, post-primary and booster vaccination. AEs incidence was similar across all groups. SAEs were reported for 117 children (29 in the 11vPHiD-CV group, 26 in the 12vPHiD-CV group, 38 in the PHiD-CV group and 24 in the PCV13 group); 4 SAEs were considered vaccination-related. No fatal events were recorded. CONCLUSION: Addition of 19A and 6A CRM197-conjugates did not alter immunogenicity of the PHiD-CV conjugates; for both investigational vaccines post-booster immune responses to 10 common serotypes appeared similar to those elicited by PHiD-CV. Safety and reactogenicity profiles of the investigational vaccines were comparable to PHiD-CV. Clinical trial registry: NCT01204658.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Carmona Martinez A, Prymula R, Miranda Valdivieso M, et al. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study. Vaccine. 2018. PMID: 30054160. doi:10.1016/j.vaccine.2018.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。